Intuitive Surgical Stock Analysis! Risks & Upside Potential
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 20 Jul 2026, 17:45 UTC
- Recorded by Tahlil Plus
- 20 Jul 2026, 18:44 UTC
AI-generated source summary
The video discusses the stock ISRG, noting its price has been declining and is currently trading around $345.42. The analysis suggests a bearish outlook, with a target price of $281.0. The failure bound for this bearish prediction is set at $360.0, meaning if the stock price rises above this level, the bearish thesis would be invalidated. The reasoning provided highlights a deceleration in revenue growth and a high P/E ratio of 39, suggesting the stock is overvalued. The analyst uses a valuation model to project future earnings and calculates that a 10% annual return would require the stock to reach $281.0 in five years. The current valuation is considered too high, with a PE ratio of 39. If the PE ratio were to drop to 25, the stock would need to be at $234, implying a significant downside.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.